Reviva Pharmaceuticals (NASDAQ:RVPH) Given Speculative Buy Rating at Benchmark

Benchmark reaffirmed their speculative buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a research report sent to investors on Tuesday morning, Benzinga reports. Benchmark currently has a $17.00 target price on the stock.

Separately, HC Wainwright reiterated a buy rating and issued a $20.00 target price on shares of Reviva Pharmaceuticals in a report on Monday, March 25th.

Reviva Pharmaceuticals Price Performance

Shares of RVPH opened at $3.02 on Tuesday. The company has a market capitalization of $84.32 million, a PE ratio of -1.84 and a beta of -0.02. Reviva Pharmaceuticals has a one year low of $2.67 and a one year high of $9.25. The company’s fifty day moving average price is $3.66 and its 200 day moving average price is $4.16.

Institutional Trading of Reviva Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in Reviva Pharmaceuticals in the 3rd quarter worth $27,000. Wells Fargo & Company MN grew its position in Reviva Pharmaceuticals by 4,550.0% in the 2nd quarter. Wells Fargo & Company MN now owns 5,115 shares of the company’s stock worth $30,000 after purchasing an additional 5,005 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Reviva Pharmaceuticals in the 1st quarter worth $31,000. Raymond James & Associates acquired a new stake in Reviva Pharmaceuticals in the 1st quarter worth $34,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Reviva Pharmaceuticals in the 4th quarter worth $52,000. 63.18% of the stock is currently owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.